Search
PC-CRP-102092 Retinal Health Wet AMD infographic.pdf
Retinal_Health_geographic_atrophy_infographic.pdf
Retinal_Health_DR infographic.pdf
Retinal_Health_Flyer_BIO-2021_bis-2021-08-03.pdf
Making More Health at a Glance.pdf
Making More Health - CREATE - Magazine Social Entrepreneurship - Edition 2023
Partnering Interests in Retinal Health
partnering-retinal-health-may-2023-corp.pdf
BI-access-to-healthcare-strategy
public health
BI_Animal_Health.pdf
190326_BI_Beethoven_Infographic_Animal-Human-Health_Final.pdf
190326_BI_Beethoven_Infographic_Animal-Human-Health_Final.pdf
Boehringer Ingelheim Animal Health Business Unit Factsheet_2.pdf
Cat Health Booklet.pdf
ForBetterHealth.pdf
Partnering in Retinal Health HP OCTOBER 2024 CORP_1.pdf
Partnering in Mental Health Disorders HP OCTOBER 2024 CORP.pdf
Corporate volunteering boosts social impact - A win for all.
Boehringer Ingelheim corporate volunteers help people with disabilities. Volunteering has social impact and benefits employees, employers, and communities.
A Unique Bond: a brotherhood like no other
After being diagnosed with diabetes, Eric’s unique bonds with Peetey and Jake meant they could run miles across the Idaho wilderness.
SENVELGO®
For the treatment of feline diabetes mellitus
FDA Grants BI 1015550 Breakthrough Therapy Designation for IPF
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550): PDE4B inhibitor